Dr. Béla Kelety

New Business Development Industrial BioSolutions

Dr. Béla Kelety, born in 1964, studied chemistry at Technische Universität Darmstadt and received his diploma after attending a study group headed by Prof. Hans Günter Gassen. He then went on to pursue his Ph.D. studies at the Max-Planck-Institute of Biophysics in Frankfurt, joining Prof. Ernst Bamberg’s group before acquiring his Ph.D. in biochemistry in 1996. During his postdoctorate he joined the cardiovascular group at Hoechst Marion Roussel AG, where he performed research on new antiarrhythmic drugs. In 1999 he took over a position at Hoechst Roussel Vet GmbH, where he was responsible for the development of high-throughput-screening (HTS) assays in the area of anti-infectives and antiparasitics. In 2001 he joined IonGate Biosciences GmbH to roll out a newly developed piece of HTS technology for transporter proteins.

Dr. Kelety joined BRAIN AG in 2010, starting in the field of skin management systems. After that he assumed a position as Managing Director of BRAIN subsidiary Mekon Science Networks GmbH, which focused on creating market access for BRAIN’s wound treatment portfolio and on developing new cosmetic brands. In April 2017, he took on responsibility for setting up and heading BRAIN’s New Business Development Unit. In the summer of 2018, he was appointed Chief Technology Officer (CTO) of SolasCure Ltd., the spin-off of BRAIN’s Aurase® development program.

In addition, he continues his work at BRAIN AG as New Business Development Manager within the Industrial BioSolutions Business Unit.

Share this page